Get started

Biotech

Jefferies $PRTA buy recommendation with price target of $6Why VistaGen Therapeutics Stock Soared yesterday The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. Why bullish? Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B . It's a nasal spray that VistaGen is evaluating in phase 2 studies targeting multiple neurological disorders. The company has already reported positive data from one of those studies, with PH94B showing promise in treating acute social anxiety disorder . There are still plenty of risks for PH94B and VistaGen's two other pipeline candidates. www.fool.com
NASDAQ:VTGN
by AlenCiken
$ONTX Closing of $28.75 Million Public Offering of Common StockOnconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference-February 16-18, 2021 finance.yahoo.com Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. A total of 28,750,000 shares of its common stock were sold, including 3,750,000 shares of common stock following the exercise by the underwriters of their over-allotment option, at a public offering price of $1.00 per share. finance.yahoo.com
O
by AlenCiken
$NVCN Regains Compliance with Nasdaq Minimum Bid Price RuleNeovasc Regains Compliance with Nasdaq Minimum Bid Price Rule Currently, the Company is still not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million; the Company has until June 8, 2021 to regain such compliance. The Company is also listed on the Toronto Stock Exchange and regaining compliance on the Nasdaq does not affect the Company’s compliance status with such listing. finance.yahoo.com
N
by AlenCiken
SONN Technical Analysis 🧙Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
SLong
by unfair_advantage
7
Topline data from the open-label, Phase 1b clinical trialDiffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million, due to demand announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. finance.yahoo.com Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting. completion and topline data from the open-label, Phase 1b clinical trial of its novel. finance.yahoo.com
D
by AlenCiken
Botanix Bullish Channel to Continue?Botanix Pharmaceuticals Ltd (ASX:BOT) is a clinical stage cannabinoid therapeutics company. The company focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. Since posting my last idea on the 16th JAN, I thought since we are at another critical level to revisit the Idea and look at 3 posible forecasts. 1. Bullish - Respect Upward Channel - MACD weak and anticipating Bullish Cross - RSI Trending Bullish towards the 50.00 Level - TB Fib Extension level 1.618 aligning with upper band of Channel NOTE: price will need to see some Strong Volume and Bullish movement to break through the Ichimoku Cloud internal of the channel (could we be so lucky to receive an announcement worthy?) 2. Bullish off Daily Support (EQ) - If price is to break Uptrend Channel then a fall to Daily Equilibrium (Support) is likely. RSI is still below the Bullish 50.00 and MACD yet to cross Bullish. Price would also have to break through the Bearish ichimoku cloud that is identified. I think that lack of news and investment frustration could see price fall before a potential Double/Triple Bottom. 3. Bearish - Break of Upward Channel - Break of Daily Support - TB Fib Extension Targets aligning with key levels of Support - RSI would break uptrend - MACD would spread and continue Bearish NOTE: If price manages to fall below Daily Support then I would expect opportunistic buying at former levels of support before reversal. The "boys" holding this down are getting weaker and starting to sweat IMO GLTAH Disclosure: Held, Sentiment: Buy "DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
ASX:BOTLong
by Trader_Johnni
1
BCRX may start an uptrendAfter a bit of correction and going down to sub $9 last week, buy side was more powerful Friday afternoon, and the SP climbed above $9.50... $10 is a first level resistance point, but once it is achieved, we can expect the SP to run towards $11.80... Support would be around $8.80 but considering the earnings was moved 2 weeks earlier (which may be a good sign), Factor D news, EU Orladeyo approval and upcoming Q1 earnings, the stock is believed to be in a positive momentum... My analysis are not investment advice. Always do your own DD and take your own decisions.
NASDAQ:BCRXLong
by StockNudge
3
Jefferies upgraded $PRTA to buy from neutral-100% upside1. Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock. Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the price target to $30 from $15, nearly double its previous close. Prothena’s pipeline has significantly expanded and improved. The company’s early-stage candidates for Alzheimer’s disease ‘should start to garner more attention,’ Yee argues, projecting the three mid-to-late-stage assets to yield ‘a significant upside.’ Add more than $300M in cash and the partnerships with Bristol Myers and Roche, the stock ‘is primed to move up 100% towards $30+,’ concluded the analyst. Out of Prothena's two candidates, PRX012 and multi-immunogen vaccine, targeting the Alzheimer’s disease, the former is on track for an IND filing in Q1 2022, the company disclosed in the recent R & D update. ------------------------------------------------------------------------------------------------------------------------------------------------- 2. BTIG Research upgraded $PRTA from neutral to buy with price target $29. seekingalpha.com
NASDAQ:PRTA
by AlenCiken
2
$ARTL surged 92% on buy rating from Ladenburg analystArtelo Biosciences surged 92% on buy initiation from Ladenburg Shares of $ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating. They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday. Ladenburg analyst cites Artelo's focus on candidates targeting the endocannabinoid system. Artelo Biosciences is a biopharma company focused on developing treatments that improve patients’ lives. That includes developing new therapies. The company’s pipeline includes ART27.13, which is designed to treat cancer patients suffering from anorexia. This treatment is currently undergoing a Phase 1 clinical trial. seekingalpha.com investorplace.com
NASDAQ:ARTL
by AlenCiken
ASRT can do this?"Assertio is a pharmaceutical company that sells prescription products in 3 areas: neurology, hospital, and pain and inflammation. The company is currently undergoing major restructuring and has recently merged with Zyla Life Sciences. They have 7 FDA approved products in the marketplace. Assertio currently has a market cap of only $150 million and has raised $50 million in direct offerings over the past week. ASRT has been on a bullish run with the price is currently up 45% in 1 week and it closed at $1.09 yesterday. This is despite 2 offerings that have been announced. The price skyrocketed off the closure of the first offering priced at $0.62 and I believe it will do the same with the current offering. Prior to the announcement of the recent offering (@$0.98), the price hit $1.45 on Tuesday. Given that the offering will not result in dilution, I believe any price under $1.1 is a good buy point" Quoting - u/TruePriest My target is 3$ depending on the earnings report next month. My RR ratio is 1:4 While we speak let's just avg down or up. (Disclaimer) (This is not financial advice, just my opinion)
NASDAQ:ASRTLong
by jackohgorman
1
Why $ANCN Anchiano Therapeutics Is Surging Today?Why $ANCN Anchiano Therapeutics Is Surging Today? Thanks to some news in December in the biopharma space, $ANCN stock is racing higher. So what was that news? And what else do you need to know? $ANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december. The proposed merger will create a public company focused on advancing Chemomab’s lead product, CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel. Concurrent with the merger, Chemomab seeks to complete a PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications, as well as to further develop Chemomab’s earlier-stage pipeline. We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger." finance.yahoo.com
A
by AlenCiken
$KALV Reports Positive Results for KVD900 Phase 2$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks – Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – There were no serious adverse events reported in the trial and no patients withdrew due to adverse events. finance.yahoo.com
NASDAQ:KALV
by AlenCiken
1